Pardes Biosciences, Inc.
PRDS
$0.02
Change (1 day)
$3.67
Year High
$0.75
Year Low
Categories
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.
Pardes Biosciences, Inc. (PRDS) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2022 | -59,284,000 | 20.43 M | 200.62 M | 200.4 M | |
| 2021 | -268,678,000 | 8.97 M | 275.26 M | 275.26 M | |
| 2020 | -3,410,000 | 16.61 M | 3.6 M | 3.6 M |